Live Program Date: Wednesday, April 7, 2021
Program Number: 21EL-622

Educational Track: Technical/Clinical
Topics: Complications, Outcomes, Patient Blood Management, Patient Transfusion, Therapeutic Goals, Transfusion Process, Transfusion Safety
Intended Audience: Hospital Blood Banks, Hospitals, Laboratory Staff, Medical Directors, Nurses, Physicians, Residents/Fellows, Students (MD, MT, SBB), Technologists, Transfusion Safety Officers
Teaching Level: Advanced, Intermediate

Faculty
(titles and affiliations at the time of the live program)
Director/Moderator: Amit Gokhale, MD, Transfusion Medicine & Coagulation Physician, Texas Children's Hospital, Assistant Professor of Pathology & Immunology, Baylor College of Medicine, Houston, TX
Speakers: Christopher Tormey, MD, Director, Transfusion Medicine Service, Yale New Haven Hospital, Director, Transfusion Medicine Fellowship, Professor of Laboratory Medicine, Yale School of Medicine, New Haven, CT; Martin A. Schreiber, MD, FACS, FCCM, Professor of Surgery, Division of Trauma, Critical Care and Acute Care Surgery, Oregon Health & Science University, Portland, OR

Program Description
Hemorrhage remains a major cause of potentially preventable morbidity and mortality in patients. Massive blood loss is encountered in various clinical situations such as trauma, major surgery, gastrointestinal bleeds, and obstetrical hemorrhage. Massive transfusion protocols (MTPs) are activated by clinicians in response to massive bleeding. MTPs have a predefined ratio of red blood cells, plasma, and platelet units in each pack for transfusion. These protocols ensure rapid and timely delivery of blood products to facilitate resuscitation. Along with conventional blood products, other blood products and pharmaceutical agents can also be of benefit. Drugs such as tranexamic acid have been shown to significantly reduce mortality in trauma patients and have been found to be beneficial in reducing bleeding in cardiac surgeries. There has also been a shift in greater use of whole blood as it has been shown that blood component therapy does not contain the same levels of platelets, coagulation factors and fibrinogen found in whole blood. This eCast will further explore the use of these and other non-conventional blood products in the setting of massive transfusion. This program will be presented though the lens of the laboratory personnel (blood banker) vs the clinician (trauma surgeon).

Learning Objectives
After participating in this educational activity, participants should be able to:

Define massive blood transfusion and massive transfusion protocol.
Identify the non-conventional blood products and pharmaceutical agents that can be potentially used during a massive transfusion.
Describe benefits and limitations of these nonconventional products vs conventional blood products.

How to Claim Continuing Education Credit

Single Viewers: if you registered as a single viewer, complete the evaluation found on the "CE Information" tab after watching the video. By submitting the evaluation, you are attesting to watching the presentation in its entirety.
Group Viewers: This is applicable for groups/facilities that purchased Group Viewing access for this program (registration will be verified prior to processing a group viewing attendance log). Group Viewing Coordinators should submit the attendance log to eLearning@aabb.org within 72 hours of the completion/viewing date. Once AABB receives an attendance log, each participant on the attendance log will be granted access as a single viewer to this program and will be required to complete the evaluation in order to claim continuing education credit. Each participant will be required to have an AABB account in order to access this program/platform. If a participant does not have an account, he/she can create one using the same email address provided on the attendance log.

Amit Gokhale MD

Transfusion Medicine & Coagulation Physician; Assistant Professor of Pathology & Immunology, Texas Children's Hospital; Baylor College of Medicine

Appearances